← Evolus, Inc. (EOLS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Evolus, Inc. (EOLS)
Pharmaceutical Preparations · market cap $532M · as of 2026-07-07
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Evolus (EOLS) is a commercial-stage pharmaceutical company focused on the aesthetics market, with its botulinum toxin Type A franchise generating $297M in 2025 revenue. The company carries $106.6M in net debt against $49.8M in cash (~15 months runway), and remains unprofitable despite four consecutive years of strong top-line growth. Its pipeline consists entirely of botulinum toxin variants targeting glabellar frown lines, making it a single-category play in the competitive neuromodulator space.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Botulinum toxin, Type A | Phase 3 | Glabellar Frown Lines |
| PrabotulinumtoxinA-Xvfs | Phase 2 | Glabellar Frown Lines |
| Botulinum purified neurotoxin, Type A | Phase 2 | Glabellar Frown Lines |
| DWP-450 (Botulinum purified neurotoxin, Type A) | Phase 2 | Glabellar Frown Lines |
Price & technical context
3-month
+11.4%
6-month
+78.4%
12-month
+25.2%
52-wk range
$3.94–$9.30
vs 50-day MA
-1.8%
vs 200-day MA
+24.9%
Realized vol
63.8%
Max drawdown
-77.5%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for EOLS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.